WAM
LGND icon

Wolverine Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Wolverine Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-285
Closed -$21K – 1289
2016
Q2 		$21K Buy
+285
New +$21.1K ﹤0.01% 1097

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Wolverine Asset Management's LGND Position: Q3 2016 in Review

Wolverine Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2016, closing a stake of 285 shares — an estimated $21K sold.

Wolverine Asset Management first reported a position in LGND in Q2 2016 and held it in 1 quarter. The position peaked at $21K in Q2 2016. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

  • Wolverine Asset Management reported no remaining Ligand Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Wolverine Asset Management sold 285 Ligand Pharmaceuticals shares in Q3 2016, an estimated $21K.
  • Wolverine Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Wolverine Asset Management's Ligand Pharmaceuticals position peaked at $21K in Q2 2016.
  • 259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Wolverine Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.